- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT01947946
Efficacy and Safety Study of Benralizumab Added to Medium-dose Inhaled Corticosteroid Plus LABA in Patients With Uncontrolled Asthma
A Multicentre, Randomized, Double-blind, Parallel Group, Placebo-controlled, Phase III Efficacy and Safety Study of Benralizumab (MEDI-563) Added to Medium-dose Inhaled Corticosteroid Plus Long-acting β2 Agonist in Patients With Uncontrolled Asthma
Panoramica dello studio
Tipo di studio
Iscrizione (Effettivo)
Fase
- Fase 3
Contatti e Sedi
Luoghi di studio
-
-
-
Buenos Aires, Argentina
- Research Site
-
Ciudad de Buenos Aire, Argentina
- Research Site
-
-
-
-
-
São Paulo, Brasile
- Research Site
-
-
-
-
-
Ruse, Bulgaria
- Research Site
-
Sofia, Bulgaria
- Research Site
-
Varna, Bulgaria
- Research Site
-
-
-
-
-
Chelyabinsk, Federazione Russa
- Research Site
-
Ekaterinburg, Federazione Russa
- Research Site
-
Izhevsk, Federazione Russa
- Research Site
-
Kazan, Federazione Russa
- Research Site
-
Moscow, Federazione Russa
- Research Site
-
Novosibirsk, Federazione Russa
- Research Site
-
Pyatigorsk, Federazione Russa
- Research Site
-
Saint Petersburg, Federazione Russa
- Research Site
-
St. Petersburg, Federazione Russa
- Research Site
-
Ulyanovsk, Federazione Russa
- Research Site
-
Vladikavkaz, Federazione Russa
- Research Site
-
-
-
-
-
Hamburg, Germania
- Research Site
-
Mainz, Germania
- Research Site
-
-
-
-
-
Bydgoszcz, Polonia
- Research Site
-
Giżycko, Polonia
- Research Site
-
Lubin, Polonia
- Research Site
-
Ostrów Wielkopolski, Polonia
- Research Site
-
Warszawa, Polonia
- Research Site
-
Wrocław, Polonia
- Research Site
-
Łódź, Polonia
- Research Site
-
Żnin, Polonia
- Research Site
-
-
-
-
Alabama
-
Birmingham, Alabama, Stati Uniti
- Research Site
-
-
Arizona
-
Glendale, Arizona, Stati Uniti
- Research Site
-
-
California
-
San Jose, California, Stati Uniti
- Research Site
-
-
Colorado
-
Centennial, Colorado, Stati Uniti
- Research Site
-
-
Florida
-
Miami, Florida, Stati Uniti
- Research Site
-
Orlando, Florida, Stati Uniti
- Research Site
-
Pembroke Pines, Florida, Stati Uniti
- Research Site
-
Winter Park, Florida, Stati Uniti
- Research Site
-
-
Georgia
-
Lawrenceville, Georgia, Stati Uniti
- Research Site
-
Savannah, Georgia, Stati Uniti
- Research Site
-
-
Nebraska
-
Bellevue, Nebraska, Stati Uniti
- Research Site
-
-
Nevada
-
Las Vegas, Nevada, Stati Uniti
- Research Site
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Stati Uniti
- Research Site
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, Stati Uniti
- Research Site
-
-
Rhode Island
-
Warwick, Rhode Island, Stati Uniti
- Research Site
-
-
South Carolina
-
Rock Hill, South Carolina, Stati Uniti
- Research Site
-
-
Texas
-
Arlington, Texas, Stati Uniti
- Research Site
-
Austin, Texas, Stati Uniti
- Research Site
-
Dallas, Texas, Stati Uniti
- Research Site
-
San Antonio, Texas, Stati Uniti
- Research Site
-
Sugarland, Texas, Stati Uniti
- Research Site
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Provision of informed consent prior to any study specific procedures
- Female and male aged from 18 to 75 years, inclusively
- History of physician-diagnosed asthma requiring treatment with medium dose ICS (>250ug fluticasone dry powder formulation equivalents total daily dose) and a LABA, for at least 12 months prior to Visit 1
- Documented treatment with medium-dose ICS (>250ug and ≤500ug fluticasone dry powder formulation equivalents total daily dose) and LABA for at least 3 month prior to Visit 1
Exclusion criteria:
- Clinically important pulmonary disease other than asthma (e.g. active lung infection, COPD, bronchiectasis, pulmonary fibrosis, cystic fibrosis, hypoventilation syndrome associated with obesity, lung cancer, alpha 1 anti-trypsin deficiency, and primary ciliary dyskinesia) or ever been diagnosed with pulmonary or systemic disease, other than asthma, that are associated with elevated peripheral eosinophil counts (e.g. allergic bronchopulmonary aspergillosis/mycosis, Churg- Strauss syndrome, hypereosinophilic syndrome)
- Any disorder, including, but not limited to, cardiovascular, gastrointestinal, hepatic, renal, neurological, musculoskeletal, infectious, endocrine, metabolic, haematological, psychiatric, or major physical impairment that is not stable in the opinion of the Investigator and could: - Affect the safety of the patient throughout the study - Influence the findings of the studies or their interpretations - Impede the patient's ability to complete the entire duration of study
- Acute upper or lower respiratory infections requiring antibiotics or antiviral medication within 30 days prior to the date informed consent is obtained or during the screening/run-in period 4. Any clinically significant abnormal findings in physical examination, vital signs, haematology, clinical chemistry, or urinalysis during screening/run-in period, which in the opinion of the Investigator, may put the patient at risk because of his/her participation in the study, or may influence the results of the study, or the patient's ability to complete entire duration of the study
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Triplicare
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
---|---|
Sperimentale: Benra 30 mg q.4 Weeks
Fixed 30 mg dose of benralizumab (every 4 weeks)
|
Benra 30 mg q.4 Weeks is a fixed 30 mg dose of benralizumab subcutaneously on study week 0 until study week 44 inclusive. Benra 30 mg - Placebo q.8 Weeks is a fixed 30 mg dose of benralizumab, every 4 weeks for the first 3 doses and then every 8 weeks thereafter, (placebo injections administrated at the 4 week interim visits to maintain blind). It is subcutaneously administered on study week 0 until study week 44 inclusive. |
Sperimentale: Benra 30 mg - Placebo q.8 Weeks
Fixed 30 mg dose of benralizumab, every 4 weeks for the first 3 doses and then every 8 weeks thereafter, (placebo injections administered at the 4 week interim treatment visits to maintain blind).
|
Benra 30 mg q.4 Weeks is a fixed 30 mg dose of benralizumab subcutaneously on study week 0 until study week 44 inclusive. Benra 30 mg - Placebo q.8 Weeks is a fixed 30 mg dose of benralizumab, every 4 weeks for the first 3 doses and then every 8 weeks thereafter, (placebo injections administrated at the 4 week interim visits to maintain blind). It is subcutaneously administered on study week 0 until study week 44 inclusive. |
Comparatore placebo: Placebo
A (Dummy) injection
|
Placebo per via sottocutanea dalla settimana 0 dello studio fino alla settimana 44 dello studio inclusa.
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
Asthma Exacerbations Over 48 Weeks Treatment
Lasso di tempo: 48 weeks treatment
|
The number of asthma exacerbations over 48 weeks treatment will be counted
|
48 weeks treatment
|
Collaboratori e investigatori
Sponsor
Investigatori
- Investigatore principale: William W. Busse, MD, Allergy, Pulmonary and Critical Care Medicine, Clinical Science Center 600 Highland Ave, Madison, WI USA
Studiare le date dei record
Studia le date principali
Inizio studio
Completamento primario (Effettivo)
Completamento dello studio (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Stima)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Stima)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- D3250C00016
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .